When's this pig gonna hit the 3 dollar mark? Anything that goes down this much should be given' really awesome HEAD.
$4.38
- Thread starter Anonymous
- Start date
-
- Tags
- None
Buying opportunity of a lifetime. Imclone's had some quarterly and annual sales volatility with Erbitux. Erbitux quarterly sales were about $160 million and gross margins were only about 40%, but John Johnson was able to sell the company to Lilly for $6.5 billion. Imclone stock was very depressed for an extended period of time. Investors who ignored all the noise (like what is posted here) became rich.
Interesting article in Forbes. Sure does apply to those seeking to destroy dendreon:
http://www.forbes.com/sites/william...s-hell-apologize-to-public-company-suing-him/
He was fortunate that an apology was enough - usually they go to jail or file for bankruptcy.
http://www.forbes.com/sites/william...s-hell-apologize-to-public-company-suing-him/
He was fortunate that an apology was enough - usually they go to jail or file for bankruptcy.
You are correct. There are attorneys that seek to bring to justice those that post false and defamatory information about a company. Given that there are posters here that are out to destroy Dendreon and post lies and misleading and defamatory information multiple times a day, there will be a treasure drove of data posted here for them to prosecute on. These posters have already posted false information that have driven sales reps away from the company. This has cost Dendreon $millions. These posters think they are Anonymous, but they are most certainly are not. This will be fun to watch.
http://www.syversonlaw.com/Internet-Law/Internet-Defamation-Libel-Slander.shtml
http://www.syversonlaw.com/Internet-Law/Internet-Defamation-Libel-Slander.shtml
Thanks. I will be fowarding the information to Dendreon corporate counsel. There will be posters that have defamed Dendreon that will regret they ever heard of this message board.
Very good analogy, the stock in question is now worth 2cents. The guy they sued was saying that the management and stock would soon be worthless.
What an idiotic defamer, it's not worthless, it's 2cents!
give him a break, it's now down to $0.01
They are going to make a big comeback though, I hear that AMGN, SNY and Celgene
are all in a bidding war for Lecere and the stock will be $20 in days.
LMAO. That angry man is the biggest laughingstock I have ever seen on any bulletin board ever. It is beyond words how creepy he is and how stupid he is. His entertainment value is off the charts
Thanks for clarifying Michael. We already knew that but this idiotic fool is trying to ruin your business model.
He also seems to think slander when it occurs is "prosecuted". In the history of America, slander has never been "prosecuted."
Additionally the idiot seems to think that truth is slander. He can't find one thing said here that isn't either opinion or truth.
February 12, 2008
CafePharma will not give Congress information about Vytorin postings.
Earlier today we wrote about a letter from the House Energy & Commerce Committee to CafePharma, Schering-Plough and Merck, requesting information about several anonymous message posts in 2007 that foretold the disastrous Vytorin results in the ENHANCE study.
The committee wrote to Sarah Palmer at CafePharma, citing all the CafePharma posts that BrandweekNRX had posted, and requested all records, names and IP addresses for the posts in question.
Sarah Palmer from CafePharma has now responded--on CafePharma:
"As we have said before, per our policies, we do not collect any user information with anonymous posts (including IP addresses). Therefore, we do not believe we will have any information to provide regarding these posts."
This response shouldn't be surprising. CafePharma has always maintained that they didn't collect IP addresses. If they were forced to turn over such information, their business model would essentially be dead, since people would stop posting. The exception seems to be people who have "registered" with CafePharma and those are virtually non-existent.
CafePharma will not give Congress information about Vytorin postings.
Earlier today we wrote about a letter from the House Energy & Commerce Committee to CafePharma, Schering-Plough and Merck, requesting information about several anonymous message posts in 2007 that foretold the disastrous Vytorin results in the ENHANCE study.
The committee wrote to Sarah Palmer at CafePharma, citing all the CafePharma posts that BrandweekNRX had posted, and requested all records, names and IP addresses for the posts in question.
Sarah Palmer from CafePharma has now responded--on CafePharma:
"As we have said before, per our policies, we do not collect any user information with anonymous posts (including IP addresses). Therefore, we do not believe we will have any information to provide regarding these posts."
This response shouldn't be surprising. CafePharma has always maintained that they didn't collect IP addresses. If they were forced to turn over such information, their business model would essentially be dead, since people would stop posting. The exception seems to be people who have "registered" with CafePharma and those are virtually non-existent.
In this case, the guy said the stock was worthless being pumped by management. They harassed him with a suit.
The stock is now a penny.
Your right Angry Guy, it could well be the D'Enron story! You nailed it with this one.
Is your high school internship in PR almost over? Good luck to ya fella, Sara Palin needs you.
LMAO!!! I think Michael from CP set him straight and that POS won't be back! He's sorry he ever heard of this site!!! Angry guy can see Russia from Seattle.
On another note this sounds similar to D'Enron. I feel sorry for Navistar and D'Enrons bondholders
Gimme Credit analyst Vicki Bryan, isn’t convinced. “Navistar’s track record on execution is grim and ICT development will take months and potentially millions to complete.” she wrote in a note to bond investors. “In the meantime we see increased pressure on operations, with falling sales, spiking costs and spending, and severely negative cash flow of more than $1 billion in 2012 alone. The company is frantically arranging $1 billion in life saving cash–albeit at near loan shark terms which reflect its substantial and rapid deterioration. Navistar has little choice. The alternative is that its dramatically weakened liquidity could prompt the company to file bankruptcy in the coming months to preserve cash while it attempts to engineer its recovery.”
Thanks for yet another screen-shot. I will not rest until you are living full-time in a room with no view. You think you can act like an 8th grader hiding behind anonymous spreading your sick lies about Dendreon. Believe me you can not hide. Coward
"From the lawsuit, which also names as defendants Dendreon's Mitchell Gold, president and chief executive; Gregory Schiffman, chief financial officer; and Hans Bishop, chief operating officer:
During the class period, as detailed herein, defendants engaged in a scheme to deceive the market, and a course of conduct that artificially inflated the price of Dendreon's securities and operated as a fraud or deceit on class period purchasers of Dendreon's securities by misrepresenting the company's financial results. Over a period of several months, defendants improperly inflated the company's financial results. Ultimately, however, when defendants' prior misrepresentations and fraudulent conduct came to be revealed and was apparent to investors, Dendreon's securities declined precipitously – evidence that the prior artificial inflation in the price of Dendreon's securities was eradicated. As a result of their purchases of Dendreon securities during the class period, plaintiff and other members of the Class suffered economic losses, i.e. damages under the federal securities laws.
By improperly characterizing the company's ability to successfully roll out its new drug and by deliberately disregarding the fact that doctors were not and would not proscribe the company's $93,000 drug without a defined reimbursement protocol, defendants presented a misleading image of Dendreon's business and future growth prospects. During the class period, defendants repeatedly emphasized the ability of the company to expand the sales growth of Provenge, and consistently reported sales growth and doctors' acceptance of this drug, within the range of guidance sponsored or endorsed by the company. These claims caused and maintained the artificial inflation in the price of Dendreon's securities throughout the class period and until the truth about the company was ultimately revealed to investors."
Read more: http://www.seattlepi.com/business/ar...#ixzz22JtjPs1w
During the class period, as detailed herein, defendants engaged in a scheme to deceive the market, and a course of conduct that artificially inflated the price of Dendreon's securities and operated as a fraud or deceit on class period purchasers of Dendreon's securities by misrepresenting the company's financial results. Over a period of several months, defendants improperly inflated the company's financial results. Ultimately, however, when defendants' prior misrepresentations and fraudulent conduct came to be revealed and was apparent to investors, Dendreon's securities declined precipitously – evidence that the prior artificial inflation in the price of Dendreon's securities was eradicated. As a result of their purchases of Dendreon securities during the class period, plaintiff and other members of the Class suffered economic losses, i.e. damages under the federal securities laws.
By improperly characterizing the company's ability to successfully roll out its new drug and by deliberately disregarding the fact that doctors were not and would not proscribe the company's $93,000 drug without a defined reimbursement protocol, defendants presented a misleading image of Dendreon's business and future growth prospects. During the class period, defendants repeatedly emphasized the ability of the company to expand the sales growth of Provenge, and consistently reported sales growth and doctors' acceptance of this drug, within the range of guidance sponsored or endorsed by the company. These claims caused and maintained the artificial inflation in the price of Dendreon's securities throughout the class period and until the truth about the company was ultimately revealed to investors."
Read more: http://www.seattlepi.com/business/ar...#ixzz22JtjPs1w
And what's the screen shot going to do for you, dimwit. You still ain't got no IP address. You know at this point you are so over board stupid that it's a good chance you're a troll who doesn't like Dendreon much and in your own, oblique manner you are putting Dendreon down by acting as it's most pathetic defender. Jesus Christ, you even got the board moderator on here today telling you you're FOS. What was it yesterday? You convinced some lady NOT to take the job at Den with your fiction about why police were at the ASM?
In a note to clients, J.P. Morgan analysts downgraded DNDN to Neutral from OW on the heels of the company's 2Q report and restructuring announcement believing that while management took difficult yet decisive action with regard to restructuring (thus lowering the breakeven threshold by 20%), the move may be too little, too late.
Wrote the analysts: "There's no denying that Provenge is about to face increasing competition in its key pre-chemo market segment. The question is whether it becomes an either/or market (i.e. Provenge or Zytiga/enzalutamide) or one where sequential therapy of effective products becomes commonplace. In the end, we think it will depend on the particular physician (and payer), but in an environment where we are still consistently surprised by the lack of understanding (by docs) of the Phase 3 IMPACT data that led to Provenge's approval, we question how quickly the majority of physicians will gravitate towards sequential therapy. With Provenge sales slipping 2% q/q ahead of Zytiga's pre-chemo approval, we'd prefer not to stick around to see how it does when Zytiga is actually readily available in this setting."
Wrote the analysts: "There's no denying that Provenge is about to face increasing competition in its key pre-chemo market segment. The question is whether it becomes an either/or market (i.e. Provenge or Zytiga/enzalutamide) or one where sequential therapy of effective products becomes commonplace. In the end, we think it will depend on the particular physician (and payer), but in an environment where we are still consistently surprised by the lack of understanding (by docs) of the Phase 3 IMPACT data that led to Provenge's approval, we question how quickly the majority of physicians will gravitate towards sequential therapy. With Provenge sales slipping 2% q/q ahead of Zytiga's pre-chemo approval, we'd prefer not to stick around to see how it does when Zytiga is actually readily available in this setting."
That same analyst was predicting $2 billion sales for provenge in 2012 just twelve months ago - so he is as clueless as the idiots that post here.